Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Diabetes

Business & Profession Business and Innovation

In Agreement

| Sponsored by PolyPhotonix

PolyPhotonix names Prevail Partners as its lead US investor whose affiliate will lead Noctura 400 FDA clinical trials

Business & Profession Professional Development

One in a Million

| Aleksandra Jones

Sitting Down With… Gladys Atto, ophthalmologist at Moroto Regional Referral Hospital, Moroto, Uganda

Subspecialties Comprehensive

Under Lock and Key

| Wei Yan Ng, Daniel Shu Wei Ting

Improving artificial intelligence development using blockchain – where digital health technologies converge

Subspecialties Retina

Pascal Synthesis Photocoagulator

| Sponsored by Iridex

The fourth iteration of Pascal Laser continues to set the standard in pattern-scanning lasers

Subspecialties Retina

Saving Sight With Light

| Sponsored by PolyPhotonix

Noctura 400 from PolyPhotonix offers a revolutionary, home-based non-invasive diabetic retinopathy treatment that reduces oxygen demand in the retina

Subspecialties Retina

Ophthalmology's Advanced Pipeline

| James Pickering

A review of gene and genetic therapies for ophthalmic conditions – and what promises they hold

Subspecialties Retina

Saving Axons and Somas

| Aleksandra Jones

Could the CaMKII enzyme help preserve vision in patients with retinal disease and eye injuries?

Business & Profession Professional Development

Leader’s Digest

| Geoffrey Potjewyd

Sitting Down With… Adam Mapani, Honorary Clinical Teaching Fellow UCL Department of Clinical Ophthalmology and Nurse Consultant at Moorfields

Subspecialties Diabetes

Sleeping Off Diabetic Retinopathy

| Sponsored by PolyPhotonix

Sharing results from a real-world single center study of patients with diabetic macular oedema (DMO) who wore a home-use sleep mask (Noctura 400)

Subspecialties Retina

Photobiomodulation: A New Approach to Retinal Disease

| Sponsored by LumiThera

The light at the end of the tunnel for dry AMD and potential for other retinal diseases consists of a multiwavelength approach to stimulate cells


Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register